Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ouabain. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 0.99 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.99 |
| ▸ | TSHR | P16473 | 2/20 | 0.99 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.99 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.99 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.99 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.99 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.99 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.99 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.99 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.99 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.99 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.99 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ouabain SCHEMBL4298579 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL14973728 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL17936503 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL10044992 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL14633742 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24951415 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960068 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL22824877 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960066 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24444049 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654841-B1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV (US) | 2024-02-07 | — | — | EP | claimed |
| US-11654292-B2 | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-05-23 | — | — | US | claimed |
| EP-3654841-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | Board Of Supervisors Of Louisiana State University (US) | 2020-05-27 | — | — | EP | claimed |
| US-20200147405-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-05-14 | — | — | US | claimed |
| CN-111132614-A | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients | 路易斯安娜州立大学监测委员会，农业和机械学院 | 2020-05-08 | — | — | CN | claimed |
| EP-2734214-B1 | TARGETED OSMOTIC LYSIS OF CANCER CELLS | UNIV LOUISIANA STATE (US) | 2019-05-29 | — | — | EP | claimed |
| WO-2019018207-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2019-01-24 | — | — | WO | claimed |
| US-20150080327-A1 | Targeted Osmotic Lysis of Cancer Cells | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2015-03-19 | — | — | US | claimed |
| US-8921320-B2 | Targeted osmotic lysis of cancer cells | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-12-30 | — | — | US | claimed |
| EP-2734214-A1 | TARGETED OSMOTIC LYSIS OF CANCER CELLS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-05-28 | — | — | EP | claimed |
| US-20130184218-A1 | Targeted Osmotic Lysis of Cancer Cells | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2013-07-18 | — | — | US | claimed |
| WO-2013012997-A1 | TARGETED OSMOTIC LYSIS OF CANCER CELLS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2013-01-24 | — | — | WO | claimed |
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-0265519-A1 | ELECTROCHEMILUMINESCENT ASSAYS. | IGEN INC (US) | 1988-05-04 | — | — | EP | disclosed |
| WO-1987006706-A1 | ELECTROCHEMILUMINESCENT ASSAYS | IGEN, INC. (US) | 1987-11-05 | — | — | WO | disclosed |
| US-4604394-A | Antiarrhythmic compositions and method | MERCK & CO., INC. (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0181762-A2 | Method for detecting enzymatic activity using particle agglutination | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | SMN1; SMN2 3818/4885TP53 3866/4885LMNA 3347/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | SMN1; SMN2 831/4885TP53 3394/4885LMNA 1554/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SMN1; SMN2 4574/4885TP53 1883/4885LMNA 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.